The prospective adalimumab biosimilar CinnoRA was shown in a recently published phase 3 trial to be comparable to AbbVie’s innovator biological treatment Humira in terms of safety and efficacy in adult patients with active rheumatoid arthritis.
The prospective adalimumab biosimilar CinnoRA (under development by CinnaGen Co, based in Alborz, Iran) was shown in a recently published phase 3 trial to be comparable to AbbVie’s innovator biological treatment Humira in terms of safety and efficacy in adult patients with active rheumatoid arthritis (RA). The study, by Ahmadreza Jamshidi, MD, professor of internal medicine, Rheumatology Research Center at Tehran University of Medical Sciences, Tehran, Iran, and colleagues, was published online in Arthritis Research & Therapy and registered with the Iranian Registry of Clinical Trials.
This randomized, double-blind, active-controlled, noninferiority trial recruited 136 adult patients with active RA to receive 40 mg subcutaneous injections of either CinnoRA or Humira every other week while receiving methotrexate (15 mg/week), folic acid (1 mg/day), and prednisolone (7.5 mg/day) over a 24-week period. Physical examinations—including vital sign evaluations and laboratory testing—were conducted at baseline, 12 weeks, and 24 weeks. The 68 patients randomized to each arm of the study had comparable demographic information, lab results, and disease characteristics at baseline; 64 patients in each group completed the 24-week study period.
The study’s primary endpoint was the proportion of patients achieving a moderate or good disease activity score of 28 (based on the European League Against Rheumatism [EULAR] response rate) in terms of joints-erythrocyte sedimentation rate (DAS28-ESR). Secondary endpoints were the proportion of patients achieving American College of Rheumatology (ACR) criteria for 20% (ACR20), 50% (ACR50), and 70% (ACR70) responses (measured as improvement in tender and swollen joint counts; patient assessments of pain, global disease activity, and physical function; physician global assessment of disease activity; and acute phase reactant), a disability index of health assessment questionnaire (HAQ), and safety.
The proportion of patients achieving good and moderate EULAR responses in the CinnoRA group was noninferior to the Humira group at 12 and 24 weeks, based on both intention-to-treat and per-protocol populations (all P values >.05). There were no significant differences in the proportion of patients achieving ACR20, ACR50, and ACR70 responses in the CinnoRA and Humira groups (all P values >.05).
The difference in HAQ scores and safety outcome measures between treatment arms was not statistically significant, the researchers noted. Four patients withdrew from the CinnoRA group due to adverse drug reactions (ADRs; n = 2), a positive tuberculin test (n = 1), and poor compliance (n = 1). Similarly, 4 patients left the Humira group because of ADRs (n = 3) and poor compliance (n = 1). The researchers did not notice any significant difference in the incidence of injection site reactions as the most prevalent adverse events between treatment arms.
Biosimilars Drive Cost Savings and Achieve 53% Market Share Across Treatment Areas
January 16th 2025Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar competition, according to Samsung Bioepis’ most recent market report, showcasing notable pricing trends and market share disparities across therapeutic areas.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Improving Biosimilar Access Through Global Regulatory Convergence
January 15th 2025Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access, reducing costs, and enhancing patient outcomes by streamlining approval processes, fostering international collaboration, and addressing regulatory disparities.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
The Next Frontier: Oncology Biosimilars in 2025 and Beyond
January 13th 2025The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer adoption, and provider confidence, with an upcoming wave of biosimilars targeting blockbuster biologics promising further market growth, cost savings, and broader patient access.
Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals
January 11th 2025Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing partnership for a denosumab biosimilar, and 2 others join forces for an eculizumab biosimilar.